A sweeping retrospective study of more than 1,600 Chinese patients with lung cancer has produced one of the most detailed maps to date of how genetic mutations shape a patient’s risk of recurrence after curative surgery. The research, conducted by a team at Shanghai Chest Hospital affiliated with Shanghai Jiao Tong University School of Medicine and published in BMC Cancer, followed 1,674 patients with stage I-IIIA non-small cell lung cancer who underwent complete surgical resection and next-generation sequencing (NGS) testing of their tumors. The central finding is striking: specific mutation patterns, particularly mutations in the TP53 gene and co-mutations involving TP53 and MET, act as powerful independent predictors of disease-free survival, offering clinicians a molecular yardstick for deciding who needs more aggressive postoperative surveillance and adjuvant therapy.
Lung cancer remains the most commonly diagnosed and deadliest malignant tumor worldwide, and while radical surgical resection is the treatment of choice for early-stage disease, postoperative recurrence continues to undermine long-term outcomes for a substantial fraction of patients. The clinical dilemma is familiar to every thoracic oncologist: two patients with seemingly identical tumor stage and histology can follow radically different trajectories after surgery, one remaining disease-free for a decade, the other relapsing within a year. Traditional staging, based on tumor size, nodal involvement and metastatic status, captures only part of this biological heterogeneity. The Shanghai team set out to determine whether the mutational landscape of resected tumors could close that gap, systematically delineating the gene mutation profile of a large real-world Chinese cohort and assessing the predictive value of critical mutations for postoperative disease-free survival (DFS).
The methodology was comprehensive. All 1,674 enrolled patients, treated between long follow-up windows and retrospectively identified from clinical records, had undergone NGS-based molecular profiling of their resected tumor specimens. The investigators collected detailed clinicopathological data, treatment information and survival outcomes, then constructed mutation profiles for the overall population and for clinically relevant subgroups. Statistical machinery included Kaplan-Meier survival curves to visualize differences in disease-free survival, univariate and multivariate Cox proportional-hazards regression to isolate the independent contribution of each genetic and clinical variable, and co-mutation analysis to test whether pairs of altered genes interact to shape prognosis more than either alteration alone.
The mutational census that emerged was broad: 144 relevant mutated genes were detected across the cohort, and the team mapped their frequencies across the population. Two alterations dominated the landscape. EGFR, the epidermal growth factor receptor gene long known to be unusually frequent in East Asian lung cancer populations, was mutated in 61.2 percent of patients, while TP53, the canonical guardian-of-the-genome tumor suppressor, was altered in 31.9 percent. The high EGFR prevalence itself underscores why population-specific genomic studies matter; mutation frequencies observed in predominantly Western cohorts do not simply translate to Chinese patients, and treatment guidelines built on foreign data risk misaligning with the biology of the patients they are meant to serve.
The prognostic signal, however, came less from EGFR than from a set of other genes. Univariate analysis revealed that patients harboring mutations in TP53, KRAS, MET, ROS1 or CDKN2A experienced significantly shorter disease-free survival than patients without those alterations. In contrast, and perhaps counterintuitively, ERBB2 mutations were associated with longer DFS, a finding that held up when the investigators pushed the data through multivariate modeling. That final model, which adjusted for confounders simultaneously, confirmed TP53 mutation, ERBB2 mutation, tumor and nodal stage (T/N classification) and pleural invasion as independent prognostic factors for postoperative disease-free survival. In other words, even after accounting for how advanced a tumor appeared anatomically, the mutational status of these genes carried genuine, standalone predictive information about whether a patient’s cancer would return.
The most consequential result concerned gene pairs. When the team performed co-mutation analysis, patients whose tumors carried both TP53 and MET mutations had the poorest prognosis of any molecular subgroup, with disease-free survival significantly worse than that of patients carrying either single mutation and dramatically worse than those wild-type for both genes. This synergistic worsening of outcome is biologically plausible: TP53 loss disables apoptotic safeguards and genomic integrity checks, while MET activation drives invasive growth and metastatic signaling pathways, and the combination may equip residual micrometastatic disease with a particularly aggressive phenotype. Critically, the TP53-MET co-mutation signal remained consistent when the analysis was repeated in the subgroup of patients whose disease did progress, reinforcing the robustness of the association rather than reflecting a statistical artifact of the full cohort.
For clinical practice, the implications are tangible. Postoperative risk stratification for lung cancer currently leans heavily on pathological stage, with adjuvant therapy decisions guided largely by nodal status and tumor size. This study provides evidence that NGS profiling of resected specimens can refine that stratification: a patient with a TP53-mutant tumor, or worse, a TP53 and MET co-mutant tumor, could be flagged for intensified surveillance imaging, consideration of adjuvant targeted therapy or chemotherapy trials, and earlier detection of recurrence through molecular monitoring. Conversely, an ERBB2-mutant patient with otherwise favorable anatomy may face a lower recurrence risk than staging alone would suggest, information that could spare unnecessary treatment toxicity. The authors explicitly frame the results as a reliable molecular basis for postoperative risk stratification and individualized adjuvant therapy in lung cancer.
The study’s scale and design give its conclusions unusual weight. Retrospective cohort studies of this kind are vulnerable to selection bias and to the vagaries of heterogeneous treatment patterns, but a sample of 1,674 consecutively sequenced patients with long-term follow-up is rare in the literature on resected lung cancer, and the concordance between univariate, multivariate and co-mutation analyses, together with validation in the progression subgroup, argues that the signals are genuine properties of the disease rather than artifacts. The work was approved by the Ethics Committee and Institutional Review Board of Shanghai Chest Hospital under reference number LS1808, conducted in line with the Declaration of Helsinki, and supported by the National Natural Science Foundation of China and the Chinese Society of Clinical Oncology. Corresponding authors Zhi-qiang Gao, Jun Lu and Bao-hui Han led the effort, with Feng Pan and Liang Zheng contributing equally as first authors.
What remains to be established is prospective validation. Retrospective association, however robust, must ultimately be tested in trials that assign adjuvant treatment based on mutational profile and measure whether outcomes improve; ongoing studies of adjuvant targeted therapy in EGFR-mutant disease suggest this paradigm is already moving into the clinic. The Shanghai data add momentum by identifying which patients, within the large EGFR-mutated population, are most and least likely to benefit from closer surveillance. As NGS testing becomes routine and cheaper for resected lung cancer specimens, studies like this one chart the path from genomic description to genomic prognosis, where every surgical specimen yields not just a diagnosis but a personalized forecast, and where the risk of recurrence, lung cancer’s most feared late event, can be anticipated and countered before the first recurrent cell ever shows up on a scan.
Subject of Research: Postoperative gene mutations as prognostic predictors of disease-free survival in Chinese patients with resected lung cancer
Article Title: Relationship between postoperative gene mutation and prognosis in chinese patients with lung cancer: a long-term follow-up retrospective cohort study
Article References: Pan, F., Zheng, L., Zhang, L.-L., Wang, X., Lu, A.-T., Zhou, C., Gao, Z.-Q., Lu, J., & Han, B.-H. (2026). Relationship between postoperative gene mutation and prognosis in chinese patients with lung cancer: a long-term follow-up retrospective cohort study. BMC Cancer. https://doi.org/10.1186/s12885-026-16960-w
Image Credits: AI Generated
DOI: 10.1186/s12885-026-16960-w
Keywords: lung cancer, gene mutation, TP53, EGFR, MET, disease-free survival, next-generation sequencing, postoperative recurrence, prognostic factors, co-mutation, retrospective cohort study, adjuvant therapy
Cite Scienmag News
APA MLA Chicago
Nathaniel Bowman. (September 12, 2026). Gene Mutations After Surgery Predict Lung Cancer Recurrence Risk in Large Chinese Cohort. Scienmag. https://scienmag.com/gene-mutations-after-surgery-predict-lung-cancer-recurrence-risk-in-large-chinese-cohort/
Nathaniel Bowman. “Gene Mutations After Surgery Predict Lung Cancer Recurrence Risk in Large Chinese Cohort.” Scienmag, 12 September 2026, https://scienmag.com/gene-mutations-after-surgery-predict-lung-cancer-recurrence-risk-in-large-chinese-cohort/. Accessed 12 September 2026.
Nathaniel Bowman. “Gene Mutations After Surgery Predict Lung Cancer Recurrence Risk in Large Chinese Cohort.” Scienmag. September 12, 2026. https://scienmag.com/gene-mutations-after-surgery-predict-lung-cancer-recurrence-risk-in-large-chinese-cohort/
Copy citation Download RIS
Tags: adjuvant therapyadjuvant therapy decision-making in lung cancerChinese lung cancer patient cohortco-mutationco-mutations in lung tumor prognosisdisease-free survivalEGFRgene mutationgenetic mutations in lung cancerimpact of genetic mutations on lung cancer outcomeslung cancerlung cancer recurrence predictionlung cancer recurrence risk factorsMETmolecular markers for lung cancer prognosisnext-generation sequencingnext-generation sequencing in lung cancerpostoperative lung cancer recurrence riskpostoperative recurrenceprognostic factorsretrospective cohort studyTP53TP53 gene mutation significancetumor mutation profiling in non-small cell lung cancer
